Microvascular disease

Renal Vascular Disease

Volumn 9781447128106, Issue , 2014, Pages 131-150

  Chade, Alejandro R ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular; Kidney; Microcirculation; Rarefaction; Remodeling; Renal function; Risk factors

Indexed keywords

EID: 84949176846     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-2810-6_8     Document Type: Chapter

References (148)

1. Chade AR. Renovascular disease, microcirculation, and the progression of renal injury: role of angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2011;300:R783-90.
2. Navar LG, Arendshorst WJ, Pallone TL, Inscho EW, Imig JD, Bell PD. The renal microcirculation. Comprehensive Physiology. 2011;550-683.
3. Hall JE. Guyton and Hall textbook of medical physiology. 12th ed. Philadelphia: Elsevier; 2011.
4. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, Johnson RJ. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis. 2001;37:601-11.
5. Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR. Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant. 2010;25:1079-87.
6. Basile DP. Rarefaction of peritubular capillaries following ischemic acute renal failure: a potential factor predisposing to progressive nephropathy. Curr Opin Nephrol Hypertens. 2004;13:1-7.
7. Chade AR, Kelsen S. Reversal of renal dysfunction by targeted administration of vegf into the stenotic kidney: a novel potential therapeutic approach. Am J Physiol Renal Physiol. 2012;302:F1342-50.
8. Chade AR, Krier JD, Rodriguez-Porcel M, Breen JF, McKusick MA, Lerman A, Lerman LO. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol. 2004;286:F1079-86.
9. Chade AR, Krier JD, Galili O, Lerman A, Lerman LO. Role of renal cortical neovascularization in experimental hypercholesterolemia. Hypertension. 2007;50:729-36.
10. Chade AR, Krier JD, Textor SC, Lerman A, Lerman LO. Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia. J Am Soc Nephrol. 2006;17:3394-403.
11. Chade AR, Lerman A, Lerman LO. Kidney in early atherosclerosis. Hypertension. 2005;45:1042-9.
12. Chade AR, Mushin OP, Zhu X, Rodriguez-Porcel M, Grande JP, Textor SC, Lerman A, Lerman LO. Pathways of renal fi brosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension. 2005;46:772-9.
13. Maric-Bilkan C, Flynn ER, Chade AR. Microvascular disease precedes the decline in renal function in the streptozotocin-induced diabetic rat. Am J Physiol Renal Physiol. 2012;302:F308-15.
14. Iliescu R, Chade AR. Progressive renal vascular proliferation and injury in obese zucker rats. Microcirculation. 2010;17:250-8.
15. Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar ME, Struijker-Boudier HA. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation. 2008;118:968-76.
16. Urbieta Caceres VH, Syed FA, Lin J, Zhu XY, Jordan KL, Bell CC, Bentley MD, Lerman A, Khosla S, Lerman LO. Age-dependent renal cortical microvascular loss in female mice. Am J Physiol Endocrinol Metab. 2012;302(8):E979-86.
17. Pessina AC. Target organs of individuals with diabetes caught between arterial stiffness and damage to the microcirculation. J Hypertens Suppl. 2007;25:S13-8.
18. Rabelink TJ, Wijewickrama DC, de Koning EJ. Peritubular endothelium: the achilles heel of the kidney? Kidney Int. 2007;72:926-30.
19. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP, Schrier RW, Schlondorff D, Cohen CD. Interstitial vascular rarefaction and reduced vegfa expression in human diabetic nephropathy. J Am Soc Nephrol. 2007;18:1765-76.
20. Mayer G. Capillary rarefaction, hypoxia, vegf and angiogenesis in chronic renal disease. Nephrol Dial Transplant. 2011;26:1132-7.
21. Basile DP, Friedrich JL, Spahic J, Knipe N, Mang H, Leonard EC, Changizi-Ashtiyani S, Bacallao RL, Molitoris BA, Sutton TA. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute kidney injury. Am J Physiol Renal Physiol. 2011;300:F721-33.
22. Bohle A, Mackensen-Haen S, von Gise H. Signifi cance of tubulointerstitial changes in the renal cortex for the excretory function and concentration ability of the kidney: a morphometric contribution. Am J Nephrol. 1987;7:421-33.
23. Chade AR, Zhu X, Lavi R, Krier JD, Pislaru S, Simari RD, Napoli C, Lerman A, Lerman LO. Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation. 2009; 119:547-57.
24. Chade AR, Zhu XY, Krier JD, Jordan KL, Textor SC, Grande JP, Lerman A, Lerman LO. Endothelial progenitor cells homing and renal repair in experimental renovascular disease. Stem Cells. 2010;28:1039-47.
25. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: ii. Vascular endothelial growth factor administration reduces renal fi brosis and stabilizes renal function. J Am Soc Nephrol. 2001;12:1448-57.
26. Bobik A. The structural basis of hypertension: vascular remodelling, rarefaction and angiogenesis/arteriogenesis. J Hypertens. 2005;23:1473-5.
27. Futrakul N, Butthep P, Laohareungpanya N, Chaisuriya P, Ratanabanangkoon K. A defective angiogenesis in chronic kidney disease. Ren Fail. 2008;30:215-7.
28. Zoccali C. Endothelial dysfunction in ckd: a new player in town? Nephrol Dial Transplant. 2008; 23:783-5.
29. Sila-asna M, Bunyaratvej A, Futrakul P, Futrakul N. Renal microvascular abnormality in chronic kidney disease. Ren Fail. 2006;28:609-10.
30. Paravicini TM, Touyz RM. Nadph oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care. 2008;31 Suppl 2:S170-80.
31. Fliser D. Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease. J Nephrol. 2011;23:369-76.
32. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983-92.
33. Chade AR. Renal vascular structure and rarefaction. Compr Physiol. 2012;3(2):817-31.
34. Giles TD, Sander GE, Nossaman BD, Kadowitz PJ. Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens (Greenwich). 2012;14:198-205.
35. Whayne Jr. TF. Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, infl ammation and endothelial dysfunction. Int J Angiol. 2007; 16:12-6.
36. Linke A, Recchia F, Zhang X, Hintze TH. Acute and chronic endothelial dysfunction: implications for the development of heart failure. Heart Fail Rev. 2003;8:87-97.
37. Gokce N, Keaney Jr. JF, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769-75.
38. Kistorp C, Chong AY, Gustafsson F, Galatius S, Raymond I, Faber J, Lip GY, Hildebrandt P. Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. Eur J Heart Fail. 2008;10:380-7.
39. Stenvinkel P. Interactions between infl ammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Ren Nutr. 2003;13:144-8.
40. Aue G, Nelson Lozier J, Tian X, Cullinane AM, Soto S, Samsel L, McCoy P, Wiestner A. Infl ammation, tnfalpha and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am J Hematol. 2011;86:835-40.
41. Mazzoccoli G, Fontana A, Grilli M, Dagostino MP, Copetti M, Pellegrini F, Vendemiale G. Idiopathic deep venous thrombosis and arterial endothelial dysfunction in the elderly. Age (Dordr). 2012;34:751-60.
42. Mazzoccoli G, Grilli M, Ferrandino F, Copetti M, Fontana A, Pellegrini F, Dagostino MP, De Cata A, Vendemiale G. Arterial endothelial dysfunction and idiopathic deep venous thrombosis. J Biol Regul Homeost Agents. 2011;25:565-73.
43. Poredos P, Jezovnik MK. In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels. 2011;26:596-602.
44. Wang D, Iversen J, Wilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int. 2003;64:1381-8.
45. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insuffi ciency. Hypertension. 2002;39:135-41.
46. Kelsen S, Hall JE, Chade AR. Endothelin-a receptor blockade slows the progression of renal injury in experimental renovascular disease. Am J Physiol Renal Physiol. 2011;301:F218-25.
47. Chade AR, Rodriguez-Porcel M, Grande JP, Krier JD, Lerman A, Romero JC, Napoli C, Lerman LO. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation. 2002;106:1165-71.
48. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Structural skin capillary rarefaction in essential hypertension. Hypertension. 1999;33: 998-1001.
49. Cambonie G, Comte B, Yzydorczyk C, Ntimbane T, Germain N, Le NL, Pladys P, Gauthier C, Lahaie I, Abran D, Lavoie JC, Nuyt AM. Antenatal antioxidant prevents adult hypertension, vascular dysfunction, and microvascular rarefaction associated with in utero exposure to a low-protein diet. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1236-45.
50. Chade AR, Rodriguez-Porcel M, Rippentrop SJ, Lerman A, Lerman LO. Angiotensin ii at1 receptor blockade improves renal perfusion in hypercholesterolemia. Am J Hypertens. 2003;16:111-5.
51. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO. Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J. 2006;20:1706-8.
52. Chade AR, Zhu XY, Grande JP, Krier JD, Lerman A, Lerman LO. Simvastatin abates development of renal fi brosis in experimental renovascular disease. J Hypertens. 2008;26:1651-60.
53. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Longterm angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome x. Am J Cardiol. 2002;90:974-82.
54. Galle J, Quaschning T, Seibold S, Wanner C. Endothelial dysfunction and infl ammation: what is the link? Kidney Int Suppl. 2003;63:S45-9.
55. Stenvinkel P. Endothelial dysfunction and infl ammation-is there a link? Nephrol Dial Transplant. 2001; 16:1968-71.
56. Biegelsen ES, Loscalzo J. Endothelial function and atherosclerosis. Coron Artery Dis. 1999;10: 241-56.
57. Leopold JA, Loscalzo J. Clinical importance of understanding vascular biology. Cardiol Rev. 2000;8: 115-23.
58. Peirce SM, Skalak TC. Microvascular remodeling: a complex continuum spanning angiogenesis to arteriogenesis. Microcirculation. 2003;10:99-111.
59. VanBavel E, Bakker EN, Pistea A, Sorop O, Spaan JA. Mechanics of microvascular remodeling. Clin Hemorheol Microcirc. 2006;34:35-41.
60. Bakker EN, Buus CL, Spaan JA, Perree J, Ganga A, Rolf TM, Sorop O, Bramsen LH, Mulvany MJ, Vanbavel E. Small artery remodeling depends on tissue-type transglutaminase. Circ Res. 2005;96: 119-26.
61. Grande JP. Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med. 1997;214:27-40.
62. Baricos WH, Cortez SL, Deboisblanc M, Xin S. Transforming growth factor-beta is a potent inhibitor of extracellular matrix degradation by cultured human mesangial cells. J Am Soc Nephrol. 1999;10:790-5.
63. McLennan SV, Kelly DJ, Schache M, Waltham M, Dy V, Langham RG, Yue DK, Gilbert RE. Advanced glycation end products decrease mesangial cell mmp-7: a role in matrix accumulation in diabetic nephropathy? Kidney Int. 2007;72:481-8.
64. Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z. Serum matrix metalloproteinases mmp-2 and mmp-9 and metalloproteinase tissue inhibitors timp-1 and timp-2 in diabetic nephropathy. J Nephrol. 2007;20:444-52.
65. Wang R, Xu YJ, Liu XS, Zeng DX, Xiang M. Knockdown of connective tissue growth factor by plasmid-based short hairpin rna prevented pulmonary vascular remodeling in cigarette smoke-exposed rats. Arch Biochem Biophys. 2011;508:93-100.
66. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by camp. FASEB J. 1999;13:1774-86.
67. Qi W, Chen X, Poronnik P, Pollock CA. Transforming growth factor-beta/connective tissue growth factor axis in the kidney. Int J Biochem Cell Biol. 2008;40:9-13.
68. Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE, Pollock CA. Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fi brosis. Am J Physiol Renal Physiol. 2005;288:F800-9.
69. Inoue T, Okada H, Kobayashi T, Watanabe Y, Kanno Y, Kopp JB, Nishida T, Takigawa M, Ueno M, Nakamura T, Suzuki H. Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fi brogenesis in 5/6 nephrectomized mice. FASEB J. 2003;17:268-70.
70. Caron A, Desrosiers RR, Langlois S, Beliveau R. Ischemia-reperfusion injury stimulates gelatinase expression and activity in kidney glomeruli. Can J Physiol Pharmacol. 2005;83:287-300.
71. Graff J, Harder S, Wahl O, Scheuermann EH, Gossmann J. Anti-infl ammatory effects of clopidogrel intake in renal transplant patients: effects on plateletleukocyte interactions, platelet cd40 ligand expression, and proinfl ammatory biomarkers. Clin Pharmacol Ther. 2005;78:468-76.
72. Kalousova M, Hodkova M, Dusilova-Sulkova S, Uhrova J, Tesar V, Zima T. Effect of hemodiafi ltration on pregnancy-associated plasma protein a (papp-a) and related parameters. Ren Fail. 2006;28:715-21.
73. Desrosiers RR, Rivard ME, Grundy PE, Annabi B. Decrease in ldl receptor-related protein expression and function correlates with advanced stages of wilms tumors. Pediatr Blood Cancer. 2006;46:40-9.
74. McLennan SV, Wang XY, Moreno V, Yue DK, Twigg SM. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology. 2004; 145:5646-55.
75. Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, Schreiner GF, Johnson RJ. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806-16.
76. Zhu XY, Rodriguez-Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, Caplice N, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation. 2004;109:2109-15.
77. Davis GE, Senger DR. Extracellular matrix mediates a molecular balance between vascular morphogenesis and regression. Curr Opin Hematol. 2008;15: 197-203.
78. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625-33.
79. Prewitt RL, Chen II, Dowell R. Development of microvascular rarefaction in the spontaneously hypertensive rat. Am J Physiol. 1982;243:H243-51.
80. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest. 1995;96:953-64.
81. Eirin A, Zhu XY, Urbieta-Caceres VH, Grande JP, Lerman A, Textor SC, Lerman LO. Persistent kidney dysfunction in swine renal artery stenosis correlates with outer cortical microvascular remodeling. Am J Physiol Renal Physiol. 2011;300:F1394-401.
82. Korn C, Augustin HG. Born to die: blood vessel regression research coming of age. Circulation. 2012;125:3063-5.
83. Wacker A, Gerhardt H. Endothelial development taking shape. Curr Opin Cell Biol. 2011;23:676-85.
84. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafi i S. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193:1005-14.
85. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafi i S. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of sdf-1, vegf, and angiopoietin-1. Ann N Y Acad Sci. 2001;938:36-45; discussion 45-7.
86. Rudnicki M, Perco P, Enrich J, Eder S, Heininger D, Bernthaler A, Wiesinger M, Sarkozi R, Noppert SJ, Schramek H, Mayer B, Oberbauer R, Mayer G. Hypoxia response and vegf-a expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest. 2009;89:337-46.
87. Nakagawa T, Lan HY, Zhu HJ, Kang DH, Schreiner GF, Johnson RJ. Differential regulation of vegf by tgfbeta and hypoxia in rat proximal tubular cells. Am J Physiol Renal Physiol. 2004;287:F658-64.
88. Olszewska-Pazdrak B, Hein TW, Olszewska P, Carney DH. Chronic hypoxia attenuates vegf signaling and angiogenic responses by downregulation of kdr in human endothelial cells. Am J Physiol Cell Physiol. 2009;296:C1162-70.
89. Gomez SI, Warner L, Haas JA, Bolterman RJ, Textor SC, Lerman LO, Romero JC. Increased hypoxia and reduced renal tubular response to furosemide detected by bold magnetic resonance imaging in swine renovascular hypertension. Am J Physiol Renal Physiol. 2009;297:F981-6.
90. Warner L, Glockner JF, Woollard J, Textor SC, Romero JC, Lerman LO. Determinations of renal cortical and medullary oxygenation using blood oxygen level-dependent magnetic resonance imaging and selective diuretics. Invest Radiol. 2011;46:41-7.
91. Zhu XY, Chade AR, Rodriguez-Porcel M, Bentley MD, Ritman EL, Lerman A, Lerman LO. Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24:1854-9.
92. Takahashi S, Shinya T, Sugiyama A. Angiostatin inhibition of vascular endothelial growth factor-stimulated nitric oxide production in endothelial cells. J Pharmacol Sci. 2010;112:432-7.
93. Zhu M, Bi X, Jia Q, Shangguan S. The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic gk rats: different expressions of angiostatin and vascular endothelial growth factor. Biomed Pharmacother. 2010;64:208-13.
94. Maeshima Y, Makino H. Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair. 2010;3:13.
95. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol. 2004;286: F893-902.
96. Watorek E, Paprocka M, Dus D, Kopec W, Klinger M. Endostatin and vascular endothelial growth factor: potential regulators of endothelial progenitor cell number in chronic kidney disease. Pol Arch Med Wewn. 2011;121:296-301.
97. Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 2005;54:2891-903.
98. Karihaloo A, Karumanchi SA, Barasch J, Jha V, Nickel CH, Yang J, Grisaru S, Bush KT, Nigam S, Rosenblum ND, Sukhatme VP, Cantley LG. Endostatin regulates branching morphogenesis of renal epithelial cells and ureteric bud. Proc Natl Acad Sci U S A. 2001;98:12509-14.
99. Maciel TT, Coutinho EL, Soares D, Achar E, Schor N, Bellini MH. Endostatin, an antiangiogenic protein, is expressed in the unilateral ureteral obstruction mice model. J Nephrol. 2008;21:753-60.
100. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, Harper SJ. Vegf165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123-31.
101. Hugo C, Daniel C. Thrombospondin in renal disease. Nephron Exp Nephrol. 2009;111:e61-6.
102. Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, Napoli C, Sawamura T, Textor SC, Lerman A, Lerman LO. Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol. 2003;23:1295-301.
103. Fujii H, Takiuchi S, Kawano Y, Fukagawa M. Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am J Hypertens. 2008;21:650-6.
104. Marcovecchio ML, Chiarelli F. Microvascular disease in children and adolescents with type 1 diabetes and obesity. Pediatr Nephrol. 2011;26:365-75.
105. Feihl F, Liaudet L, Waeber B. The macrocirculation and microcirculation of hypertension. Curr Hypertens Rep. 2009;11:182-9.
106. Greene AS, Tonellato PJ, Lui J, Lombard JH, Cowley Jr. AW. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol. 1989;256:H126-31.
107. Cowley Jr. AW, Roman RJ, Krieger JE. Pathways linking renal excretion and arterial pressure with vascular structure and function. Clin Exp Pharmacol Physiol. 1991;18:21-7.
108. Brecker CG, Shustak SR. Contractile proteins in endothelial cells: comparison of cerebral capillaries with those in heart and skeletal muscle and with liver sinusoids. Circulation. 1972;45/46(Suppl II):87.
109. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2003;284:R893-912.
110. Romero JC, Reckelhoff JF. State-of-the-art lecture. Role of angiotensin and oxidative stress in essential hypertension. Hypertension. 1999;34:943-9.
111. Romero JC, Reckelhoff JF. Oxidative stress may explain how hypertension is maintained by normal levels of angiotensin ii. Braz J Med Biol Res. 2000;33:653-60.
112. Chatziantoniou C, Boffa JJ, Tharaux PL, Flamant M, Ronco P, Dussaule JC. Progression and regression in renal vascular and glomerular fi brosis. Int J Exp Pathol. 2004;85:1-11.
113. Battegay EJ, de Miguel LS, Petrimpol M, Humar R. Effects of anti-hypertensive drugs on vessel rarefaction. Curr Opin Pharmacol. 2007;7:151-7.
114. Josifova T, Schneider U, Henrich PB, Schrader W. Eye disorders in diabetes: potential drug targets. Infect Disord Drug Targets. 2008;8:70-5.
115. Marin P, Andersson B, Krotkiewski M, Bjorntorp P. Muscle fi ber composition and capillary density in women and men with niddm. Diabetes Care. 1994;17:382-6.
116. Futrakul N, Futrakul P. Renal microvascular disease predicts renal function in diabetes. Ren Fail. 2012;34:126-9.
117. Gomes MB, Affonso FS, Cailleaux S, Almeida AL, Pinto LF, Tibirica E. Glucose levels observed in daily clinical practice induce endothelial dysfunction in the rabbit macro-and microcirculation. Fundam Clin Pharmacol. 2004;18:339-46.
118. Ko SH, Cao W, Liu Z. Hypertension management and microvascular insulin resistance in diabetes. Curr Hypertens Rep. 2011;12:243-51.
119. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S424-37.
120. O'Donovan HC, Hickey F, Brazil DP, Kavanagh DH, Oliver N, Martin F, Godson C, Crean J. Connective tissue growth factor antagonizes transforming growth factor-beta1/smad signalling in renal mesangial cells. Biochem J. 2012;441:499-510.
121. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, Striker LJ. Igf-1 decreases collagen degradation in diabetic nod mesangial cells: implications for diabetic nephropathy. Diabetes. 1999;48: 1638-44.
122. Zhang J, Zhang X, Li H, Cui X, Guan X, Tang K, Jin C, Cheng M. Hyperglycaemia exerts deleterious effects on late endothelial progenitor cell secretion actions. Diab Vasc Dis Res. 2013;10(1):49-56.
123. Biscetti F, Pitocco D, Straface G, Zaccardi F, de Cristofaro R, Rizzo P, Lancellotti S, Arena V, Stigliano E, Musella T, Ghirlanda G, Flex A. Glycaemic variability affects ischaemia-induced angiogenesis in diabetic mice. Clin Sci (Lond). 2011;121:555-64.
124. Nakagawa T. Uncoupling of the vegf-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of vegf in renal disease. Am J Physiol Renal Physiol. 2007;292: F1665-72.
125. Siervo M, Tomatis V, Stephan BC, Feelisch M, Bluck LJ. Vegf is indirectly associated with no production and acutely increases in response to hyperglycaemia( 1). Eur J Clin Invest. 2012;42:967-73.
126. Hohenstein B, Hausknecht B, Boehmer K, Riess R, Brekken RA, Hugo CP. Local vegf activity but not vegf expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2006;69:1654-61.
127. Futrakul N, Futrakul P. Vascular homeostasis and angiogenesis determine therapeutic effectiveness in type 2 diabetes. Int J Vasc Med. 2011;2011:971524.
128. O'Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial disease in persons with renal insuffi ciency: results from the national health and nutrition examination survey 1999-2000. Circulation. 2004;109:320-3.
129. Bax L, van der Graaf Y, Rabelink AJ, Algra A, Beutler JJ, Mali WP. Infl uence of atherosclerosis on age-related changes in renal size and function. Eur J Clin Invest. 2003;33:34-40.
130. Safi an RD, Textor SC. Renal-artery stenosis. N Engl J Med. 2001;344:431-42.
131. Dworkin LD, Murphy T. Is there any reason to stent atherosclerotic renal artery stenosis? Am J Kidney Dis. 2010;56:259-63.
132. Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC, Ishani A, Collins AJ, Foley RN. Atherosclerotic renovascular disease in united states patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005;68:293-301.
133. Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, Burke GL, Dean RH. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg. 2002;36:443-51.
134. Lerman LO, Taler SJ, Textor SC, Sheedy 2nd PF, Stanson AW, Romero JC. Computed tomography-derived intrarenal blood flow in renovascular and essential hypertension. Kidney Int. 1996;49:846-54.
135. Textor SC, Wilcox CS. Renal artery stenosis: a common, treatable cause of renal failure? Annu Rev Med. 2001;52:421-42.
136. Textor SC. Ischemic nephropathy: where are we now? J Am Soc Nephrol. 2004;15:1974-82.
137. Chade AR, Best PJ, Rodriguez-Porcel M, Herrmann J, Zhu X, Sawamura T, Napoli C, Lerman A, Lerman LO. Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. Kidney Int. 2003;64:962-9.
138. Chade AR, Rodriguez-Porcel M, Herrmann J, Zhu X, Grande JP, Napoli C, Lerman A, Lerman LO. Antioxidant intervention blunts renal injury in experimental renovascular disease. J Am Soc Nephrol. 2004;15:958-66.
139. Chavakis E, Dernbach E, Hermann C, Mondorf UF, Zeiher AM, Dimmeler S. Oxidized ldl inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the akt/ endothelial nitric oxide synthase pathway. Circulation. 2001;103:2102-7.
140. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the united states. Obes Rev. 2005;6:5-7.
141. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among us children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847-50.
142. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11:1278-89.
143. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, Rood JC, Burk DH, Smith SR. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and infl ammation without an angiogenic response. Diabetes. 2009;58:718-25.
144. de Jongh RT, Serne EH, IJ RG, de Vries G, Stehouwer CD. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation. 2004;109:2529-35.
145. Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang XL, Sayre J, Dahlbom M, Licinio J, Schelbert HR. Relationship between increasing body weight, insulin resistance, infl ammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol. 2006;47: 1188-95.
146. Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens. 2003; 12:195-200.
147. Warncke J, David S, Kumpers P, Opherk JP, Haller H, Fliser D. A hibernating kidney-ischemic preconditioning in a renal transplant recipient with a proximal stenosis of the iliac artery. Clin Nephrol. 2008;70:168-71.
148. Cheung CM, Chrysochou C, Shurrab AE, Buckley DL, Cowie A, Kalra PA. Effects of renal volume and single-kidney glomerular fi ltration rate on renal functional outcome in atherosclerotic renal artery stenosis. Nephrol Dial Transplant. 2010;25: 1133-40.